Market Overview

BofA Expects Dentsply Sirona's Performance To Improve With New Product Ramp, Cost-Cutting

BofA Expects Dentsply Sirona's Performance To Improve With New Product Ramp, Cost-Cutting

Dentsply Sirona Inc (NASDAQ: XRAY) is in the midst of a major transition.

Potential cost savings should support EPS, and the dental equipment supplier could achieve more consistent revenue growth due to new product launches and a slight improvement in the dental market, according to Bank of America Merrill Lynch. 

The Analyst

BofA's Michael Cherny reinstated coverage of Dentsply Sirona with a Buy rating and a $57 price target.

The Thesis

Dentsply Sirona has made significant changes to its technology portfolio while enacting better cost management, Cherny said in a Monday note. 

The company is working hard to simplify the business and looks poised to execute well on its cost savings plan, the analyst said. This will allow Dentsply Sirona to achieve a more stable total return profile into FY20 and beyond, even if revenue growth slows from historical rates, he said. 

The Primescan standalone digital impression launch and other new products introduced by the company should boost demand, Cherny said. 

With improvements in standalone digital impression technology, Dentsply Sirona needs to focus on monetizing its position, in BofA's view.

Price Action

Dentsply Sirona shares were trading flat at $49.09 at the time of publication Monday. 

Related Links:

Benzinga's Top Upgrades, Downgrades For March 16, 2019

The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials And Earnings 

Latest Ratings for XRAY

Jul 2019Initiates Coverage OnIn-Line
Apr 2019Initiates Coverage OnNeutral
Mar 2019ReinstatesBuy

View More Analyst Ratings for XRAY
View the Latest Analyst Ratings

Posted-In: BofA Merrill Lynch Michael ChernyAnalyst Color Price Target Analyst Ratings Best of Benzinga


Related Articles (XRAY)

View Comments and Join the Discussion!

Latest Ratings

WUBABOCOM InternationalDowngrades
DLTROTR GlobalUpgrades
ARCCCompass PointDowngrades
GTYHCitiInitiates Coverage On7.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

Dare Bioscience Skyrockets On Positive Data For Vaginal Dryness Drug

Beto O'Rourke Raises More Than $6M Online On Day One Of Campaign